Introduction
============

Clinical evidence indicates that depression and anxiety disorders are heterogeneous in their phenomenology, etiology and treatment responses. There is a strong association between these emotional disorders and metabolic syndrome.^[@bib1],\ [@bib2]^ However, the underlying biological mechanisms remain to be established. Responses to environmental challenges involve complex interactions between the nervous and endocrine systems. White adipose tissue, previously viewed as a passive organ for energy storage, is now recognized as an active metabolic and endocrine organ. It secrets a number of hormones, termed adipokines, that exert pleiotropic physiological functions.^[@bib3]^ Adipose tissue dysfunction causes aberrant production and secretion of adipokines, which is known to contribute to the pathogenesis of metabolic syndrome.^[@bib3]^ Some adipokines are able to cross the blood--brain-barrier (BBB), mediating the crosstalk between adipose tissue and brain through modulating neuronal excitability, synaptic plasticity and contributing to neural circuit remodeling.^[@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13]^ Although much is known about the regulation of adipose tissue function and adipokine production by metabolic states, little is known of the role of adipose tissue in behavioral responses to emotional stress and how adipokine production is regulated under stress conditions.

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor that belongs to the nuclear receptor family.^[@bib14]^ It exists in two isoforms, PPARγ1 and PPARγ2, which are generated from the same gene by alternative splicing.^[@bib15]^ PPARγ1 is abundantly expressed in adipose tissue but also found in other tissues, whereas PPARγ2 is restricted to adipose tissue.^[@bib16]^ PPARγ is essential for the formation of adipocytes;^[@bib17],\ [@bib18]^ mice null for the PPARγ gene are completely lacking adipose tissue.^[@bib18]^ PPARγ plays a key role in gene expression of adipokines.^[@bib19],\ [@bib20],\ [@bib21]^ Adiponectin is the most abundant adipokine in the circulation and exclusively secreted from adipose tissue.^[@bib22],\ [@bib23]^ Thiazolidinediones, synthetic ligands of PPARγ including rosiglitazone and pioglitazone, induce the adiponectin promoter activity and increase adiponectin expression in adipocytes, which parallels elevated adiponectin levels in the circulation.^[@bib19],\ [@bib24],\ [@bib25],\ [@bib26]^ These effects of thiazolidinediones can be blocked by the selective PPARγ antagonist GW9662.^[@bib27]^ PPARγ agonists are widely used to treat type 2 diabetes through improving insulin sensitivity,^[@bib28]^ which is partially mediated through induction of adiponectin.^[@bib29],\ [@bib30]^

We have previously shown that adiponectin levels are decreased by chronic social defeat stress,^[@bib31]^ an animal model of depression, post-traumatic stress disorder and other anxiety-related disorders.^[@bib11],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34]^ Adiponectin insufficiency increases susceptibility to social defeat stress, and intracranial administration of adiponectin reduces depression- and post-traumatic stress disorder-related symptoms.^[@bib9],\ [@bib31],\ [@bib35]^ However, whether its upstream positive regulator PPARγ in adipose tissue participates in mediating susceptibility to stress and emotion-related behaviors remains to be elucidated. In the present study, we investigated the effects of chronic social defeat stress on adipose PPARγ expression and its relationships with adiponectin production and stress vulnerability. This stress model was selected as socially defeated mice can be segregated into stress-susceptible and stress-resilient subpopulations based upon their social interaction behavior,^[@bib32],\ [@bib33]^ which provides a valuable system to study the molecular basis of susceptibility and resilience to emotional stress. We further examined whether activation of PPARγ by peripherally administered rosiglitazone, a BBB-impermeant PPARγ agonist, is capable of producing antidepressant- and anxiolytic-like effects within a relatively short-time frame, and whether the presence of adiponectin is required for behavioral responses to rosiglitazone. We found that chronic social defeat decreased adipose PPARγ and adiponectin production in susceptible mice but not in the resilient subpopulation. Activation of PPARγ produced antidepressant- and anxiolytic-like effects through an adiponectin-dependent mechanism. These results indicate an important role for the adipose PPARγ-adiponectin axis in stress responses and emotion-related behavioral regulation.

Materials and methods
=====================

Animals
-------

Male and female wild-type C57BL/6J mice were purchased from Jackson Laboratory and maintained a breeding colony. CD1 mice were purchased from Vital River Laboratory Animal Technology (Beijing, China). Heterozygous adiponectin knockout (Adipo^+/−^) mice were originally obtained from Dr. Philipp Scherer (UT Southwestern, Dallas, TX, USA)^[@bib29]^ and backcrossed on the C57BL/6J background for more than 10 generations. Adipo^+/−^ mice were intercrossed to generate homozygous mutant offspring and wild-type littermates. Mice were housed in a 12:12 h light--dark-cycle (light on at 0700 hours) with *ad libitum* access to food and water. Male mice at 8--12 weeks of age were used for the experiments. All animal procedures were approved by the Institutional Animal Care and Use Committee at Binzhou Medical University Hospital and the University of Texas Health Science Center at San Antonio.

Drugs
-----

Rosiglitazone potassium salt (Cayman Chemical Company, Ann Arbor, MI, USA) was dissolved in normal saline (0.9% NaCl w/v) before use. For acute treatment, a single intraperitoneal (i.p.) dose of rosiglitazone (10 mg/kg) was given to mice 1 h or 3 h before collecting blood and adipose tissue samples or performing behavioral tests. For multiple treatments, mice were given three i.p. injections of rosiglitazone (10 mg/kg) either once daily over 3 days or 3 times within 24 h (23.5 h, 3 h and 1 h); the last injection was given 1 h before collecting blood and tissue samples or behavioral testing. The dose of 10 mg/kg rosiglitazone for i.p. injection was chosen based upon its effectiveness in improving insulin tolerance in mice.^[@bib25]^ The selective PPARγ antagonist GW9662 (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in dimethyl sulfoxide, diluted to a final concentration of 0.2 mg/ml in 0.9% saline containing 1% dimethyl sulfoxide, and given i.p. injection (2 mg/kg) 30 min before administration of rosiglitazone or saline. This dose and timing of injection of GW9662 have been reported to block the actions of PPARγ agonists.^[@bib36],\ [@bib37]^ All mice were weighed before experiment and randomly assigned to different treatment groups.

Chronic social defeat
---------------------

Social defeat was generated using a resident--intruder paradigm as previously reported with minor modifications.^[@bib11],\ [@bib31],\ [@bib34]^ Adult male CD1 mice were co-housed with two female CD1 mating partners at least 3 weeks. Subsequently, male sexually experienced CD1 mice were housed individually for 1 week before being screened for aggression. During the screening process, a 'screener' C57BL/6J mouse was introduced into the cage of a singly housed CD1 mouse for 3 min/session and three sessions/day and the latency of the CD1 mouse to attack the 'screener' C57BL/6J mouse during each session was recorded. The screening procedure was repeated for 3 consecutive days. The CD1 mice with the attack latency \<60 s for at least two sessions on the last day were selected for use as resident aggressors in social defeat experiments. All aggressors were rescreened in three consecutive sessions to ensure aggressiveness of CD1 mice before use in subsequent social defeat experiments.

For the chronic social defeat procedure, male C57BL/6J experimental mice were individually placed into the home cage of an aggressive CD1 mouse for 10 min during which time the experimental mouse was physically defeated. Thereafter, the CD1 resident mouse and the C57BL/6J intruder were housed together but separated by a perforated plastic divider to allow visual, olfactory and auditory contact for the remainder of the 24-h period. C57BL/6J mouse was exposed to a new resident CD1 mouse and subjected to social defeat each day for 10 consecutive days. Control mice were housed two per cage in the cages identical to those used for socially defeated mice. Social interaction was assessed at 24 h after the last social defeat session, which was performed in a box (40 × 40 × 40 cm) with infrared light illumination. Each social interaction test consisted of two 2.5-min sessions. In the first 2.5-min 'no target' session, the C57BL/6J mouse was placed into the open arena with an empty wire mesh cage (10 × 6.5 × 5 cm) at the middle of one side of the box. For the second 2.5-min session with 'target', an unfamiliar CD1 male mouse was placed into the wire mesh cage. The time spent by the C57BL/6J mouse in the 'interaction zone' (25 × 14 cm) surrounding the wire mesh cage was measured. Social interaction ratio was calculated as time spent in the interaction zone in the presence of a social target divided by the time spent in interaction zone without a social target.

Forced swim test
----------------

Mice were placed into a clear Plexiglas cylinder (25 cm in height and 10 cm in diameter) filled with water (24 ºC) for a 15-min pretest, followed 24 h later by a 6-min forced swim test session.^[@bib31],\ [@bib38]^ The latency to immobility and the duration of immobility during the pretest and in the last 4 min of the test were measured. Immobility was defined as no active movements except those required for respiration.

Elevated plus-maze test
-----------------------

This test is a widely used anxiety paradigm, which is based on the natural conflict between the drive to explore a new environment and the tendency to avoid a potentially dangerous area.^[@bib39]^ The elevated plus-maze consisted of 4 arms (35-cm long and 5-cm wide) arranged in the shape of a 'plus' sign and elevated to a height of 70 cm from the floor. Two arms have no side or end walls (open arms) and the other two arms have side walls and end walls but are open on top (closed arms). The open and closed arms intersect, having a central 5 × 5-cm square platform giving access to all arms. As described previously,^[@bib10],\ [@bib11],\ [@bib40],\ [@bib41]^ mice were placed in the central square facing the corner between a closed arm and an open arm and allowed to explore the elevated plus-maze for 5 min. Their activity was videotaped. The numbers of entries made into each arm and the time spent on the open and closed arms were measured. The degree of anxiety was assessed by calculating the percentage of open arm entries (entries into the open arms/total entries into all arms) and percentage of time spent in the open arms (time spent in open arms/total time spent in all arms).

Novelty-suppressed feeding test
-------------------------------

This test is a behavioral model of anxiety based on the conflict between hunger and aversion to a brightly lit, novel environment. The apparatus consisted of a box (60 × 60 × 40 cm) filled with 2 cm of bedding on the floor. As described previously,^[@bib10],\ [@bib40]^ a single food pellet was placed on a round filter paper (11 cm in diameter) located in the center of the arena. Mice were food-deprived for 24 h before being placed at the corner of the box and monitored for 10 min. The latency for the animal to approach the food in the center and feed was measured. Immediately after the test, mice were transferred back to their home cage and food consumption was measured for 5 min.

Locomotor activity
------------------

The locomotor activity was measured in an open field box (40 × 40 × 40 cm). Mice were placed in the open field arena and allowed to freely explore for 30 min.^[@bib11]^ A charge coupled device camera was mounted above the open box for recording locomotor activity. The total distance traveled was measured in 2-min bins using Any-maze software (Stoelting, Wood Dale, IL, USA).

The experimenters who scored the behaviors were blind to animals' genotypes and treatment conditions.

Western blot assay
------------------

Mice were decapitated rapidly, and trunk blood was collected in tubes containing 20 μl of 0.5% ethylenediaminetetraacetic acid disodium and centrifuged at 1000*g* for 10 min. The supernatant plasma was collected and stored at −20 ºC. The epididymal fat pads were removed, frozen in liquid nitrogen and stored at −80 °C before being processed for western blotting. White adipose tissue was homogenized in the lysis buffer (Beyotime Biotechnology, Shanghai, China) with 1% phenylmethylsulfonyl fluoride (Sangon Biotech, Shanghai, China) and 1 × PhosSTOP phosphatase inhibitor cocktail (Roche Applied Science, Penzberg, Germany). Western blotting was performed as describe elsewhere.^[@bib31],\ [@bib42],\ [@bib43]^ In brief, adipose tissue lysate or plasma samples were mixed with 5 × sodium dodecyl sulfate--polyacrylamide gel electrophoresis loading dye (Beyotime Biotechnology) and denatured by boiling at 100 °C for 10 min. Denatured proteins (20 μg adipose tissue lysate or 5 μl 10-fold diluted plasma sample) were separated on an sodium dodecyl sulfate--polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane. The membrane was blocked in Tris-buffered saline containing 1% dried milk and 0.1% Tween 20, and then incubated with the following primary antibodies overnight at 4 ºC: anti-adiponectin (Cat. \#AF1119, 1:1000, R&D systems, Minneapolis, MN, USA), anti-PPARγ (Cat. \#sc-7273, 1:500, Santa Cruz Biotechnology, Dallas, TX, USA) and anti-β-actin (Cat. \#4970, 1:3000, Cell Signaling Technology, Danvers, MA, USA). After washing, membranes were incubated with secondary antibodies: donkey anti-goat IgG (Cat. \#926-32214), donkey anti-mouse IgG (Cat. \#926-68072) and goat anti-rabbit IgG (Cat. \#926-32211) (1:5000, LI-COR Biosciences, Lincoln, NE, USA). Signals were visualized and quantitatively analyzed with Odyssey Sa Quantitative Infrared Imaging System (LI-COR Biosciences). Adiponectin levels were normalized to IgG in plasma and normalized to β-actin in adipose tissue.

Blood glucose levels
--------------------

Trunk blood was collected when mice were decapitated. Blood glucose levels were measured using a glucometer (Bayer HealthCare LLC, Mishawaka, IN, USA).

Real-time RT-PCR
----------------

White fat tissue was homogenized and total RNA was extracted with the total RNA rapid extraction kit (Generay Biotechnology, Shanghai, China). HiScript II QRT SuperMix (Vazyme, Nanjing, China) was used to generate cDNA according to following procedure: 1 μg of total RNA and 4 × gDNA Wiper mix were incubated at 42 °C for 2 min to remove genome contamination, then 5 × HiScript II QRT SuperMix was added to the reaction mixture and incubated at 25 °C for 10 min, 50 °C for 30 min, and 85^ ^°C for 5 min. The resulting cDNA was used for real-time PCR detection using the StepOnePlus real-time PCR system (Applied Biosystems, Waltham, MA, USA) with AceQ qPCR SYBR green master mix (Vazyme). The condition for PCR was 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. The primer sequences used to amplify each product were as follows: mouse *Adiponectin*,^[@bib31]^ forward-5′-CAGGCATCCCAGGACATCC-3′, reverse-5′-CCAAGAAGACCTGCATCTCCTTT-3′ mouse *PPARγ*,^[@bib44]^ forward-5′-ATCTACACGATGCTGGC-3′, reverse-5′-GGATGTCCTCGATGGG-3′ mouse *PPARγ1*,^[@bib45]^ forward-5′-TTTAAAAACAAGACTACCCTTTACT-3′, reverse-5′-AGAGGTCCACAGAGCTGATTCC-3′ mouse *PPARγ2*,^[@bib45]^ forward-5′-GATGCACTGCCTATGAGCACTT-3′, reverse-5′-AGAGGTCCACAGAGCTGATTCC-3′ mouse *β-actin*,^[@bib46]^ forward-5′-GATCATTGCTCCTCCTGAGC-3′, reverse-5′-ACTCCTGCTTGCTGATCCAC-3′. Samples were run in triplicates and the s.d. was ranged from 0.026 to 0.15. The ΔΔCT method was used to obtain relative fold-change of target gene expression normalized by the housekeeping gene *β-actin* compared with control samples.^[@bib47]^ *β-actin* gene has been validated as a stable and suitable reference gene for gene expression studies, particularly in adipose tissue.^[@bib48],\ [@bib49]^ A plot of the log cDNA dilution *versus* ΔCT (*target gene* -- *β-actin*) was made. The absolute values of the slopes (*Adiponectin* - *β-actin*, −0.0094; *PPARγ1* - *β-actin*, −0.027; *PPARγ2* - *β-actin*, 0.0087; *PPARγ* - *β-actin*, −0.0199) close to zero confirmed the validity of the ΔΔCT method.

Statistical analyses
--------------------

Statistical significance was assessed by one-way analysis of variance (ANOVA), two-way ANOVA, two-way repeated-measures ANOVA or two-tailed *t*-tests, where appropriate. Significant effects in the analysis of variances were followed up with Bonferroni *post hoc* tests. The linear relationships between two variables were determined by calculating Pearson's correlation coefficient. Results were considered significantly different when *P*\<0.05. All data were presented as mean±s.e.m.

Results
=======

Regulation of PPARγ and adiponection expression in adipose tissue by chronic social stress
------------------------------------------------------------------------------------------

Adult male C57BL/6J mice were defeated daily by different CD1 mice for 10 consecutive days followed by a social interaction test 24 h after the last defeat session. Mice with a social interaction ratio (ratio of time spent in the interaction zone in the presence versus absence of a social target) \<1 were defined as susceptible, whereas the mice with a social interaction ratio \>1 were defined as resilient ([Figure 1a](#fig1){ref-type="fig"}). Body weight was measured at the end of the social defeat experiment, which showed no difference between control mice and socially defeated mice ([Figure 1a](#fig1){ref-type="fig"}). To identify the involvement of adipose PPARγ in susceptibility and resilience to social defeat stress, we measured PPARγ mRNA and protein levels in adipose tissue of susceptible and resilient mice in comparison with control mice. Chronic social defeat decreased total *PPARγ* mRNA levels in susceptible mice, but not in resilient subgroup ([Figure 1b](#fig1){ref-type="fig"}). Further analysis of *PPARγ1* and *PPARγ2* mRNA revealed that levels of *PPARγ2* mRNA, but not *PPARγ1* mRNA, were reduced in adipose tissue of susceptible mice compared with control and resilient mice ([Figure 1b](#fig1){ref-type="fig"}). Positive correlations were observed between social interaction ratio and total *PPARγ* mRNA or *PPARγ2* mRNA, but not between social interaction ratio and *PPARγ1* mRNA, in socially defeated mice ([Figure 1b](#fig1){ref-type="fig"}). In parallel with mRNA expression, adipose PPARγ protein levels were decreased in susceptible mice ([Figure 1c](#fig1){ref-type="fig"}). There was a significant correlation between adipose PPARγ protein levels and social interaction behavior ([Figure 1c](#fig1){ref-type="fig"}). Correspondingly, mRNA and protein levels of adiponectin were decreased in adipose tissue of susceptible mice compared with control and resilient mice ([Figures 1d and e](#fig1){ref-type="fig"}). These results suggest a functional role of the adipose PPARγ and adiponectin in susceptibility and resilience to social defeat stress.

Effects of PPARγ activation on adiponectin levels: single versus multiple rosiglitazone injections
--------------------------------------------------------------------------------------------------

As a direct transcriptional target of PPARγ, adiponectin was expected to be upregulated in a relatively short-term frame after treatment with PPARγ agonists. We therefore examined adiponectin expression in response to a single and multiple (three times) i.p. injections of rosiglitazone (10 mg/kg), a highly selective and potent PPARγ agonist.^[@bib50]^ We found that a single i.p. injection failed to increase mRNA and protein expression of adiponectin in adipose tissue or plasma at 1 h and 3 h after injection ([Figures 2a--c](#fig2){ref-type="fig"}). Multiple injections of rosiglitazone, that is, 3 i.p. injections over 3 days (once daily) or within 24 h (23.5, 3 and 1 h before blood and tissue collection) significantly increased mRNA levels and protein expression of adiponectin in adipose tissue and plasma adiponectin concentrations ([Figures 2a--c](#fig2){ref-type="fig"}). Blood glucose levels were not altered in any of these rosiglitazone treatment groups ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}). Body weight exhibited no significant difference between vehicle and rosiglitazone treatment groups ([Supplementary Figure S1b](#sup1){ref-type="supplementary-material"}).

Antidepressant-like effect of rosiglitazone is abolished in adiponectin knockout mice
-------------------------------------------------------------------------------------

The antidepressant-like effect of rosiglitazone was assessed in a modified forced swim test. Wild-type mice were first subjected to a 15-min pretest swim session, and next day received a single i.p. injection of rosiglitazone (10 mg/kg) 1 h before the 6-min test. This rosiglitazone treatment had no effect on the latency and duration of immobility in the forced swim ([Figure 3a1](#fig3){ref-type="fig"}). Plasma adiponectin levels measured immediately after the forced swim test showed no significant difference between rosiglitazone- and vehicle-treated groups ([Figure 3a1](#fig3){ref-type="fig"}). Next, we tested the multiple injection treatment regimen. After a 15-min pretest, mice received 3 i.p. injections of rosiglitazone (10 mg/kg) 23.5, 3 and 1 h before the testing session. This treatment regimen significantly increased the latency to immobility and reduced immobility duration in the forced swim test, accompanied by an increase in plasma adiponectin levels measured after the test ([Figure 3a](#fig3){ref-type="fig"}2). Given that increased locomotor activity could confound the interpretation of results from the forced swim test, we examined the locomotor response to rosiglitazone in an open field. Mice that received 3 i.p. injections of rosiglitazone (10 mg/kg; 23.5, 3 and 1 h) or vehicle showed no difference in the distance traveled during the 30 min test ([Figure 3a3](#fig3){ref-type="fig"}).

To determine whether increased adiponectin levels contribute to the rosiglitazone-induced antidepressant-like effect, adiponectin knockout (Adipo^−/−^) mice received the same treatment with multiple rosiglitazone injections after a pretest. In the absence of adiponectin, rosiglitazone failed to induce significant change in either latency or duration of immobility in the forced swim test ([Figure 3b](#fig3){ref-type="fig"}), suggesting that adiponectin is necessary for the antidepressant-like effect of rosiglitazone. Moreover, we compared Adipo^−/−^ mice with wild-type littermate controls in the forced swim test. Under basal conditions, Adipo^−/−^ mice demonstrated immobility levels that were comparable to wild-type littermate controls ([Supplementary Figure S2a](#sup1){ref-type="supplementary-material"}).

Anxiolytic effects of rosiglitazone are abolished in adiponectin knockout mice
------------------------------------------------------------------------------

To evaluate whether rosiglitazone regulates anxiety-related behavior, wild-type mice received a single i.p. injection (10 mg/kg) 1 h before a 5-min elevated plus-maze test. No effect was observed on the entries made into open arms or the time spent on open arms ([Figure 4a](#fig4){ref-type="fig"}). However, multiple rosiglitazone injections (23.5, 3 and 1 h before the test) significantly increased the percentage of open-arm entries and open-arm time ([Figure 4a](#fig4){ref-type="fig"}), suggesting an anxiolytic-like effect. This effect of rosiglitazone was abolished in Adipo^−/−^ mice ([Figure 4a](#fig4){ref-type="fig"}). Under basal conditions Adipo^−/−^ mice exhibited no differences in open arm entries and open arm time compared with wild-type littermate control mice ([Supplementary Figure S2b](#sup1){ref-type="supplementary-material"}). Furthermore, we examined the anxiolytic effect of rosiglitazone in the novelty-suppressed feeding test, another behavioral model of anxiety. Mice were first deprived of food for 24 h and then received 3 i.p. injections of rosiglitazone 23.5, 3 and 1 h before measuring the latency for the animal to approach a food pellet located in the center of an open area. In wild-type mice, rosiglitazone significantly decreased the latency of wild-type mice to feed without affecting home-cage food consumption within 5 min immediately after the test ([Figure 4b](#fig4){ref-type="fig"}). However, this effect of rosiglitazone was absent in Adipo^−/−^ mice ([Figure 4b](#fig4){ref-type="fig"}). These data suggest that the anxiolytic-like effects of rosiglitazone requires the presence of adiponectin.

PPARγ expression is unaltered in adiponectin knockout mice
----------------------------------------------------------

One possibility for the absence of antidepressant- and anxiolytic-like effects of rosiglitazone in Adipo^−/−^ mice could result from downregulation of PPARγ due to adiponectin deficiency. To address this, levels of total *PPARγ*, *PPARγ1* and *PPARγ2* mRNA were measured in adipose tissue. There were no differences in mRNA levels for *PPARγ*, *PPARγ1* and *PPARγ2* between Adipo^−/−^ mice and littermate control mice ([Supplementary Figure S3a](#sup1){ref-type="supplementary-material"}). In addition, we determined the effects of adiponectin deficiency on *PPARγ1* and *PPARγ2* mRNA expression in the brain. Only *PPARγ1* mRNA was detected in the brain, such as the hippocampus and prefrontal cortex. In both brain regions, Adipo^−/−^ mice and wild-type littermate controls showed comparable levels of *PPARγ1* mRNA expression ([Supplementary Figure S3b](#sup1){ref-type="supplementary-material"}). These data indicate that PPARγ expression in adipose tissue and brain is not affected in Adipo^−/−^ mice.

Rosiglitazone-induced increase in adiponectin production is PPAR*γ*-dependent
-----------------------------------------------------------------------------

Rosiglitazone has been shown to exert both PPAR*γ*-dependent and PPAR*γ*-independent effects on metabolism.^[@bib51]^ To examine whether the effect of rosiglitazone on adiponectin levels is dependent on PPARγ activation, GW9662, a selective PPARγ antagonist, was administered to mice 30 min before each rosiglitazone injection, which was given 23.5, 3 and 1 h before blood and tissue collection. Blockade of PPARγ with GW9662 significantly attenuated the effects of rosiglitazone on adiponectin mRNA and protein levels in adipose tissue ([Figure 5a1](#fig5){ref-type="fig"}). Correspondingly, pretreatment with GW9662 also blocked the rosiglitazone-induced increase in plasma adiponectin levels ([Figure 5a2](#fig5){ref-type="fig"}).

Effects of rosiglitazone on depression- and anxiety-related behaviors are PPAR*γ*-dependent
-------------------------------------------------------------------------------------------

To confirm that the rosiglitazone-induced antidepressant-like effect is PPAR*γ*-dependent, mice were first subjected to a 15-min pretest and then pretreated with GW9662 30 min before each rosiglitazone injection that was given 23.5, 3 and 1 h before the forced swim test. Although GW9662 alone had no effect on immobility in this test, it blocked the rosiglitazone-induced increase in latency to immobility and decrease in immobility duration ([Figure 5b](#fig5){ref-type="fig"}). To test that whether the anxiolytic-like effects of rosiglitazone are dependent on PPAR*γ*, mice received the same pretreatment with GW9662 and treatment with rosiglitazone followed by a 5-min elevated plus-maze test. The rosiglitazone-induced increase in open-arm entries and open-arm time was antagonized by GW9662 ([Figure 5c](#fig5){ref-type="fig"}). In the novelty-suppressed feeding test, pretreatment with GW9662 attenuated the effect of rosiglitazone on latency to feed without changing home-cage food consumption ([Figure 5d](#fig5){ref-type="fig"}). These results suggest that PPAR*γ* activation is responsible for the antidepressant/anxiolytic-like effects of rosiglitazone.

Discussion
==========

In this study we aimed to uncover a novel role for adipose PPARγ in stress susceptibility and negative emotional behaviors. We show that chronic social defeat stress decreased PPARγ mRNA and protein levels in adipose tissue of susceptible but not resilient mice, which coincided with social avoidance behavior. A parallel decrease in adiponectin production was observed in adipose tissue of susceptible mice, which is consistent with the role of PPARγ as the key transcription factor controlling adiponectin expression.^[@bib19],\ [@bib24]^ We further show that PPARγ activation by rosiglitazone increased adiponectin production and produced antidepressant- and anxiolytic-like effects. Adiponectin is essential for PPARγ-mediated effects on depression- and anxiety-related behaviors.

The PPARγ gene generates two isoforms, *PPARγ1* and *PPARγ2*, by alternative splicing and promoter usage.^[@bib15],\ [@bib52]^ They differ in their N terminal protein sequence. PPARγ2 contains 30 extra amino acids on the N-terminus,^[@bib15]^ which confer a 5--10-fold increase in transcription-stimulating activity.^[@bib53]^ In this study, we found that *PPARγ1* and *PPARγ2* were differentially regulated in adipose tissue in relation to vulnerability and resilience to chronic social defeat stress. Susceptible mice showed significant decrease in mRNA levels of total *PPARγ* and *PPARγ2* but not *PPARγ1* compared with control and resilient mice. Consistent with the mRNA results, PPARγ protein levels in adipose tissue was also reduced in susceptible mice but not in resilient mice. As a transcription factor, the reduction of PPARγ activity was expected to inhibit expression of the target genes.^[@bib54],\ [@bib55]^ Indeed, both mRNA and protein levels of adiponectin in adipose tissue were found to be decreased by chronic social defeat in susceptible mice but not in the resilient subgroup. These findings suggest that suppression of the adipose PPARγ-adiponectin axis activity may participate in determining susceptibility and resilience to stress. This notion was further supported by our previous finding that adiponectin insufficiency increases susceptibility to social defeat stress.^[@bib31]^ However, what mechanisms mediate social defeat-induced PPARγ downregulation is currently unknown. One possibility would be an overactive state of the sympathetic nervous system induced by chronic social defeat stress.^[@bib56],\ [@bib57]^ Sympathetic nerve fibers directly innervate white adipose tissue and release norepinephrine at neuro-adipose junctions.^[@bib58],\ [@bib59]^ It has been reported that norepinephrine represses *PPARγ2* gene expression in adipocytes.^[@bib60]^ An overactive sympathetic nervous system and elevated norepinephrine levels in adipose tissue under chronic stress may lead to PPARγ downregulation.

The selective agonists for PPARγ, including rosiglitazone and pioglitazone, are currently prescribed for the treatment of type 2 diabetes.^[@bib50],\ [@bib61]^ They have been widely used as a pharmacological tool for defining the functions of PPARγ.^[@bib62]^ Previous studies have shown that rosiglitazone increases adiponectin levels after 7 days to 15 week of i.p. or oral administration.^[@bib26],\ [@bib63],\ [@bib64]^ These studies, however, cannot rule out the possibility that induction of adiponectin may occur secondary, at least in part, to body weight reduction and metabolic syndrome alleviation due to chronic treatment with rosiglitazone.^[@bib65],\ [@bib66]^ In the present study, we determined the effects of a single and multiple injections of rosiglitazone on adiponectin levels within a relatively short-time frame. Although a single i.p. injection failed to elevate adiponectin levels in adipose tissue and plasma 1 h or 3 h after injection, multiple injections within 24 h (23.5, 3 and 1 h) or in 3 consecutive days significantly increased adiponectin mRNA and protein expression in adipose tissue and plasma levels without altering glucose concentrations and body weight. This suggests that rosiglitazone-induced adiponectin production precedes its metabolic actions.

Both the single and multiple i.p. injection treatment regimens have been used to test the efficacy of antidepressants in the forced swim test in rodents.^[@bib67]^ We found that multiple injections of rosiglitazone (within 24 h), but not the single injection treatment, significantly reduced immobility, an index of behavioral 'despair', in the forced swim test. This is generally consistent with a previous report showing that oral administration of rosiglitazone for 5 days decreases immobility in rats and mice.^[@bib36]^ Furthermore, we found that the antidepressant-like effect of rosiglitazone was associated with increased circulating adiponectin levels measured immediately after the forced swim test. The time lag between rosiglitazone treatment and antidepressant-like behavioral effects may be explained by the time required to induce adiponectin synthesis/secretion and achieve an effective concentration. Our investigations with Adipo^−/−^ mice confirmed that adiponectin is necessary for the antidepressant-like effects of rosiglitazone. Similarly, we found that rosiglitazone elicited anxiolytic-like effects the elevated plus-maze and novelty-suppressed feeding tests. These anxiolytic-like effects of rosiglitazone also require the presence of adiponectin. Given the fact that adiponectin is expressed exclusively in adipose tissue^[@bib22]^ and our observation of the blockade of behavioral responses to rosiglitazone by pretreatment with the selective PPARγ antagonist GW9662, we propose that the antidepressant/anxiolytic-like effects of rosiglitazone are dependent on activation of PPARγ in adipose tissue through the induction of adiponectin. Adiponectin exists in different oligomers in the circulation, that is, trimers, hexamers and high-molecular-weight multimers.^[@bib68],\ [@bib69]^ Trimers and hexamers can cross the BBB and detected in the cerebrospinal fluid of humans and mice.^[@bib70],\ [@bib71],\ [@bib72]^ Two adiponectin receptors, AdipoR1 and AdipoR2, are found to be highly expressed in brain regions implicated in depression and anxiety disorders, such as the hippocampus and prefrontal cortex,^[@bib8],\ [@bib31]^ where adiponectin may exert its antidepressant- and anxiolytic effects.

We chose to use rosiglitazone to activate PPARγ in this study because this drug is thought to be impermeable to the intact BBB in rodents, thus confining its effects to peripheral tissues.^[@bib73],\ [@bib74]^ Rosiglitazone is a substrate of P-glycoprotein, a major drug efflux transporter in the BBB,^[@bib75]^ which limits its penetration into the brain.^[@bib76]^ However, under certain circumstances, neurological insults such as Alzheimer's disease and stroke can cause breakdown of the BBB, which increases permeability of the BBB to rosiglitazone.^[@bib77],\ [@bib78]^ Studies have suggested that activation of brain PPARγ produces antidepressant-like effects. Direct infusion of rosiglitazone into the brain reduces immobility time in the forced swim test.^[@bib79]^ Pioglitazone, another PPARγ agonist that can cross the BBB, also elicit antidepressant-like effects.^[@bib37]^ The question is then raised whether activation of brain PPARγ may contribute to the antidepressant/anxiolytic-like effects induced by peripherally administered rosiglitazone. The absence of antidepressant/anxiolytic-like effects of rosiglitazone in Adipo^−/−^ mice, however, ruled out this possibility. Adipo^−/−^ mice showed normal PPARγ expression levels in the brain. If brain PPARγ is involved in mediating rosiglitazone-induced behavioral effects, one would expect that rosiglitazone remains to be effective in Adipo^−/−^ mice in the forced swim test and the elevated plus-maze test. Moreover, we demonstrated that PPARγ expression was unaltered in adipose tissue of Adipo^−/−^ mice, suggesting that the unresponsiveness of Adipo^−/−^ mice to rosiglitazone is not due to downregulation of adipose PPARγ. The use of conditional knockout mice with tissue-specific deletion of PPARγ will help to further clarify the role of PPARγ in adipose tissue in stress responses and emotion-related behaviors.

Depressive disorders are highly prevalent, along with the growing epidemic of obesity and type 2 diabetes. Despite the well-established association between these conditions,^[@bib1],\ [@bib80],\ [@bib81],\ [@bib82],\ [@bib83]^ the underlying causes remain to be identified. Both PPARγ and adiponectin are important players in the pathogenesis of obesity and type 2 diabetes. The development of obesity requires the continuous differentiation of new adipocytes, which is controlled by PPARγ.^[@bib17],\ [@bib18]^ Adiponectin levels are reduced in obese and type 2 diabetes patients.^[@bib84],\ [@bib85],\ [@bib86],\ [@bib87]^ These findings, together with our current observation of downregulation of adipose PPARγ and adiponectin in the chronic stress model of depression and our previous finding of adiponectin insufficiency increasing susceptibility for stress-induced depressive-like behavior,^[@bib31]^ suggest that PPARγ and adiponectin dysregulation may be the shared common biological pathways for obesity, type 2 diabetes and depression. The PPARγ agonists and other stimulators of adiponectin used for diabetes and metabolic syndrome may be effective against depression.

In conclusion, the present study provide evidence for a novel role of adipose PPARγ in susceptibility and resilience to chronic stress and a functional link between PPARγ and adiponectin in mediating emotion-related behaviors. Our results suggest that the PPARγ-adiponectin axis is involved, not only in maintaining metabolic homeostasis but also in maintaining emotional homeostasis under stress. Given that the BBB presents a real challenge in drug development for neuropsychiatric disorders, our findings implicate that PPARγ and its targets in adipose tissue may be a promising pharmacological target to combat depression, anxiety, and other stress-related disorders.
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![Regulation of messenger RNA (mRNA) and protein levels of PPARγ and adiponectin in adipose tissue by chronic social defeat stress. (**a**) Upper, timeline of chronic social defeat procedure. Lower-left, schematic representation of the social interaction test. Lower-middle, time spent in the interaction zone with and without the target CD1 mouse (subgroup: *F*~(2,30)~=27.470, *P*\<0.001; target: *F*~(1,30)~=22.281, *P*\<0.001; subgroup × target interaction: *F*~(2,30)~=45.329, *P*\<0.001. \*\*\**P*\<0.001 compared with the absence of a social target, ^\#\#\#^*P*\<0.001 compared with the control group in the presence of a social target, ^+++^*P*\<0.001 compared with the resilient group in the presence of a social target. Lower-right, body weight of chronic social defeat stress mice on day 12 (*F*~(2,30)~=0.177, *P*\>0.05). (**b**) Upper, mRNA levels of *PPARγ* (left: *F*~(2,30)~=9.180, *P*\<0.001), *PPARγ1* (middle: *F*~(2,30)~=1.399, *P*\>0.05) and *PPARγ2* (right: *F*~(2,30)~=6.166, *P*\<0.01) in adipose tissue. \*\**P*\<0.01, \*\*\**P*\<0.001 compared with the control group, ^\#^*P*\<0.05 compared with the resilient group. Lower, correlation between mRNA levels of *PPARγ*, *PPARγ1* and *PPARγ2* and social interaction ratio in mice subjected to chronic social defeat stress (left: *r*=0.442, *P*\<0.05; middle: *r*=0.246, *P*\>0.05; right: *r*=0.582, *P*\<0.01). CSD, chronic social defeat. (**c**) Left, immunoblots of PPARγ proteins in adipose tissue. Middle, quantification of PPARγ protein (*F*~(2,30)~=4.943, *P*\<0.05). Right, correlation analysis between PPARγ protein and social interaction ratio in CSD mice (Pearson correlation, *r*=0.527, *P*\<0.05). \**P*\<0.05 compared with the control group, ^\#\#^*P*\<0.01 compared with the resilient group. (**d**) Adiponectin mRNA in adipose tissue (*F*~(2,30)~=9.748, *P*\<0.001). \*\*\**P*\<0.001 compared with the control group, ^\#\#\#^*P*\<0.001 compared with the resilient group. (**e**) Immunoblots (left) and quantification (right) of adiponectin protein in adipose tissue (*F*~(2,30)~=6.945, *P*\<0.01). \*\**P*\<0.01 compared with the control group, ^\#\#^*P*\<0.01 compared with the resilient group. Control, *n*=12; susceptible, *n*=10; resilient, *n*=11. Data are shown as mean±s.e.m.](mp2016225f1){#fig1}

![Effects of single and multiple rosiglitazone injections on adiponectin transcription and secretion. (**a**) Adiponectin mRNA levels in adipose tissue after single (1 h or 3 h before testing; 1 ×, 1 h and 1 ×, 3 h treatments) and three injections of rosiglitazone (10 mg/kg, i.p.) over 3 days (3 ×, 3d) or within 24 h (3 ×, 24 h). Left: 1 ×, 1 h; *t*~(8)~=0.607, *P*\>0.05. Middle-left: 1 ×, 3 h; *t*~(8)~=0.8291, *P*\>0.05. Middle-right: 3 ×, 3d; *t*~(8)~=2.306, *P*\<0.05. Right: 3 ×, 24 h; *t*~(8)~=2.777, *P*\<0.05. (**b**) Upper, immunoblots of adiponectin protein in adipose tissue. Lower, quantification of adiponectin protein levels. Left: 1 ×, 1 h; *t*~(8)~=1.389, *P*\>0.05. Middle-left: 1 ×, 3 h; *t*~(8)~=0.484, *P*\>0.05. Middle-right: 3 ×, 3d; *t*~(8)~=4.630, *P*\<0.01. Right: 3 ×, 24 h; *t*~(8)~=2.434, *P*\<0.05). (**c**) Upper, immunoblots of plasma adiponectin after single and multiple rosiglitazone injections. Lower, quantification of adiponectin levels (Left: 1 ×, 1 h; *t*~(8)~=0.5624, *P*\>0.05. Middle-left: 1 ×, 3 h; *t*~(8)~=0.928, *P*\>0.05. Middle-right: 3 ×, 3d; *t*~(8)~=3.765, *P*\<0.01. Right: 3 ×, 24 h; *t*~(8)~=5.443, *P*\<0.001). *n*=5 per group. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with the saline-treated group. Data are shown as mean±s.e.m.](mp2016225f2){#fig2}

![Effects of rosiglitazone on depression-related behaviors in wild-type and Adipo^−/−^ mice. All mice were subjected to a 15-min pretest followed 24 h later by a 6-min forced swim test. (**a1**) Forced swim test performed 1 h after a single rosiglitazone injection (1 ×, 1 h) in wild-type (WT) mice. Left: latency to immobility; *t*~(18)~=0.203, *P*\>0.05. Middle-left: immobility time; *t*~(18)~=0.707, *P*\>0.05. Middle-right: immunoblots of plasma adiponectin measured immediately after the test. Right: quantification of plasma adiponectin levels (*t*~(18)~=0.461, *P*\>0.05). *n*=10 per group. (**a2**) Forced swim test performed following three injections of rosiglitazone within 24 h (3 ×, 24 h) in WT mice. Left: latency to immobility; *t*~(12)~=3.659, *P*\<0.01. Middle-left: immobility time; *t*~(12)~=4.263, *P*\<0.01. Middle-right, Immunoblots of plasma adiponectin measured immediately after the test. Right: quantification of plasma adiponectin levels (*t*~*(*12)~=4.777, *P*\<0.001). *n*=7 per group. (**a3**) Locomotor activity. Left: time course of locomotor activity after three injections of rosiglitazone within 24 h (time: *F*~(14,182)~=5.990, *P*\<0.001; treatment: *F*~(1,13)~=0.001, *P*\>0.05; time × treatment interaction: *F*~(14,182)~=0.873, *P*\>0.05). Right: total distance (*t*~(13)~=0.032, *P*\>0.05). Saline, *n*=7; Rosiglitazone, *n*=8. (**b**) Forced swim test performed following three injections of rosiglitazone within 24 h (3 ×, 24 h) in Adipo^−/−^ mice. Left: latency to immobility; *t*~(14)~=0.115, *P*\>0.05. Right: immobility time; *t*~(14)~=0.0739, *P*\>0.05. *n*=8 per group. \*\**P*\<0.01, \*\*\**P*\<0.001 compared with the saline-treated group. Data are shown as mean±s.e.m.](mp2016225f3){#fig3}

![Effects of rosiglitazone on anxiety-related behaviors in wild-type and Adipo^−/−^ mice. (**a**) Upper, elevated plus-maze test performed 1 h after a single rosiglitazone injection (1 ×, 1 h) in wild-type (WT) mice (Upper-left: percentage of open arm entries; *t*~(18)~=0.192, *P*\>0.05; upper-middle: percentage of open arm time; *t*~(18)~=0.480, *P*\>0.05; upper-right: total arm entries; *t*~(18)~=0.3369, *P*\>0.05). *n*=10 per group. Middle, elevated plus-maze test performed in WT mice following three rosiglitazone injections within 24 h (3 ×, 24 h). Middle-left: percentage of open arm entries; *t*~(14)~=2.837, *P*\<0.05. Middle-middle: percentage of open arm time; *t*~(14)~=3.044, *P*\<0.01. Middle-right: total arm entries; *t*~(14)~=1.348, *P*\>0.05. *n*=8 per group. Lower, elevated plus-maze test performed in Adipo^−/−^ mice following three rosiglitazone injections within 24 h (3 ×, 24 h). Lower-left: percentage of open arm entries; *t*~(18)~=0.0719, *P*\>0.05. Lower-middle: percentage of open arm time; *t*~(18)~=0.0116, *P*\>0.05. Lower-right: total arm entries; *t*~(18)~=0.5084, *P*\>0.05. *n*=10 per group. (**b**) Novelty-suppressed feeding test following three rosiglitazone injections within 24 h in WT mice and Adipo^−/−^ mice. Left, latency to feed of WT mice (*t*~(14)~=2.915, *P*\<0.05). Middle-left, home-cage food consumption of WT mice (*t*~(14)~=0.8228, *P*\>0.05). *n*=8 per group. Middle-right, latency to feed of Adipo^−/−^ mice (*t*~(14)~=0.0466, *P*\>0.05). Right, home-cage food consumption of Adipo^−/−^ mice (*t*~(14)~=0.799, *P*\>0.05). *n*=8 per group. \**P*\<0.05, \*\**P*\<0.01 compared with the saline-treated group. Data are shown as mean±s.e.m.](mp2016225f4){#fig4}

![Effects of GW9662 on rosiglitazone-induced adiponectin expression and antidepressant- and anxiolytic-like behavioral responses in wild-type mice. (**a**1) Adipose adiponectin mRNA and protein levels. Left, *adiponectin* mRNA levels (pretreatment: *F*~(1,16)~=3.641, *P*\<0.05; treatment: *F*~(1,16)~=2.050, *P*\>0.05; interaction: *F*~(1,19)~=8.506, *P*\<0.05). Right, representative immunoblots and quantification of adiponectin protein expression (pretreatment: *F*~(1,16)~=7.783, *P*\<0.05; treatment: *F*~(1,16)~=4.895, *P*\<0.05; interaction: *F*~(1,16)~=4.678, *P*\<0.05). *n*=5 per group. (**a**2) Plasma adiponectin. Representative immunoblots and quantification of plasma adiponectin levels (pretreatment: *F*~(1,16)~=5.017, *P*\<0.05; treatment: *F*~(1,16)~=1.640, *P*\>0.05; interaction: *F*~(1,16)~=10.705, *P*\<0.05). *n*=5 per group. (**b**) Forced swim test. Left, latency to immobility (pretreatment: *F*~(1,28)~=9.754, *P*\<0.01; treatment: *F*~(1,28)~=6.690, *P*\<0.05; interaction: *F*~(1,28)~=7.102, *P*\<0.05). Right, immobility time (pretreatment: *F*~(1,28)~=17.939, *P*\<0.001; treatment: *F*~(1,28)~=16.331, *P*\<0.001; interaction: *F*~(1,28)~=14.190, *P*\<0.001). *n*=8 per group. (**c**) Elevated plus-maze test. Left, percentage of open arm entries (pretreatment: *F*~(1,32)~=2.237, *P*\>0.05; treatment: *F*~(1,32)~=4.234, *P*\<0.05; interaction: *F*~(1,32)~=6.571, *P*\<0.05). Middle, percentage of open arm time (pretreatment: *F*~(1,32)~=1.584, *P*\>0.05; treatment: *F*~(1,32)~=3.356, *P*\>0.05; interaction: *F*~(1,32)~=4.854, *P*\<0.05). Right, total arm entries (pretreatment: *F*~(1,32)~=0.417, *P*\>0.05; treatment: *F*~(1,32)~=0.031, *P*\>0.05; interaction: *F*~(1,32)~=0.996, *P*\>0.05). *n*=9 per group. (**d**) Novelty-suppressed feeding test. Left, latency to feed (pretreatment: *F*~(1,32)~=1.004, *P*\>0.05; treatment: *F*~(1,32)~=5.059, *P*\<0.05; interaction: *F*~(1,32)~=1.390, *P*\>0.05). Right, home-cage food consumption in 5 min after the test (pretreatment: *F*~(1,32)~=0.304, *P*\>0.05; treatment: *F*~(1,32)~=0.123, *P*\>0.05; interaction: *F*~(1,32)~=0.003, *P*\>0.05). *n*=9 per group. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with the Vehicle+Vehicle treatment group; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 compared with the Vehicle+Rosiglitazone treatment group. Data are shown as mean±s.e.m.](mp2016225f5){#fig5}
